<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00612339</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00001022</org_study_id>
    <nct_id>NCT00612339</nct_id>
  </id_info>
  <brief_title>Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas</brief_title>
  <official_title>Avastin in Combination With Temozolomide for Unresectable or Multifocal Glioblastoma Multiformes and Gliosarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective- To determine efficacy of Avastin, 10 mg/kg every other week, in
      combination with standard 5-day temozolomide in terms of response rate.

      Secondary objective- To determine safety of Avastin &amp; Temozolomide in unresectable
      glioblastoma patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects have histologically confirmed WHO gr IV primary malignant glioma that is
      unresectable/multifocal. This is Phase II study where up to 41 subjects will receive up to 4
      cycles of Avastin &amp; Temozolomide. Avastin administered at 10 mg/kg every 14 days beginning a
      minimum of 7 days after biopsy/28 days after craniotomy. Temozolomide dosed at 200 mg/m2
      daily for 5 days in 28-day cycle. Patients will receive up to 4 cycles of Avastin &amp;
      Temozolomide, then proceed with standard XRT. Study will use 2-stage &quot;minimax&quot; study design
      in which 21 subjects are accrued during 1st stage, with possibility that additional 20
      patients accrued during 2nd stage. In initial Phase I &amp; II trials, 4 potential
      Avastin-associated safety signals were identified: hypertension, proteinuria, thromboembolic
      events, &amp; hemorrhage. Avastin-associated adverse events in Phase III trials include
      congestive heart failure, GI perforations, wound healing complications, &amp; arterial
      thromboembolic events. Most common toxicity associated with Temozolomide has been mild
      myelosuppression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>4 months</time_frame>
    <description>The proportion of subjects with complete or partial response as determined by a modification of the RANO (Response Assessment in Neuro-Oncology) criteria. A confirmation of response was not required. Complete Response was defined as complete disappearance on MR/CT of all enhancing tumor and mass effect, off all corticosteroids (or receiving only adrenal replacement doses), accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks. Partial Response was defined as greater than or equal to 50% reduction in tumor size on MR/CT by bi-dimensional measurement, on a stable or decreasing dose of corticosteroids, accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Gliosarcoma</condition>
  <arm_group>
    <arm_group_label>Avastin and Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avastin administered at 10 mg/kg every 2 weeks beginning a minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide dosed at 200 mg/m2 daily for 5 days in a 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin and Temozolomide</intervention_name>
    <description>This is Phase II study with the combination of Avastin &amp; Temozolomide for unresectable or multifocal WHO grade IV malignant glioma patients. Patients will receive up to 4 cycles of Avastin &amp; Temozolomide . Avastin administered at 10 mg/kg every 14 days beginning minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide will be dosed at 200 mg/m2 daily x 5 days in 28-day cycle. Patients will have baseline MRI &amp; repeat MRI every 4 weeks. If there is no evidence of disease progression after each cycle, or unacceptable toxicity, or as determined by investigators, patient non-compliance or patient withdraws consent to continue therapy &amp; requests discontinuation, patients will receive up to 4 cycles of Avastin &amp; Temozolomide, then proceed with standard XRT therapy, &amp; future therapy after 4 cycles will be at discretion of patient &amp; treating physicians.</description>
    <arm_group_label>Avastin and Temozolomide</arm_group_label>
    <other_name>Avastin - Bevacizumab</other_name>
    <other_name>Temozolomide - Temodar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients have histologically confirmed diagnosis of WHO gr IV primary malignant glioma.
        Patients will be unresectable or have multifocal disease.

          -  Age ≥ 18years &amp; life expectancy of &gt;12 weeks

          -  Evidence of measurable primary CNS neoplasm on contrast enhanced MRI.

          -  Interval of &lt;1 week between prior biopsy/4 weeks from surgical resection &amp; enrollment
             on protocol

          -  Karnofsky ≥60%

          -  Hemoglobin ≥9g/dl, ANC ≥1,500 cells/microliter, platelets ≥125,000 cells/microliter

          -  Serum creatinine ≤1.5 mg/dl, serum SGOT &amp; bilirubin ≤1.5 x ULN

          -  For patients on corticosteroids, they must have been on stable dose for 1 week prior
             to entry, if clinically possible, &amp; dose should not be escalated over entry dose level

          -  Signed informed consent approved by IRB prior to patient entry

          -  No evidence of &gt; grade 1 CNS hemorrhage on baseline MRI/CT scan

          -  If sexually active, patients will take contraceptive measures for duration of
             treatments

        Exclusion Criteria:

          -  Pregnancy/breast feeding

          -  Co-medication that may interfere with study results

          -  Active infection requiring IV antibiotics

          -  Prior or current Treatment w XRT/chemo for brain tumor, irrespective of grade of tumor

          -  Evidence of &gt; grade 1 CNS hemorrhage on baseline MRI or CT scan

        Avastin-Specific Concerns:

          -  Inadequately controlled hypertension

          -  Any prior history of hypertensive crisis/hypertensive encephalopathy

          -  New York Heart Association Grade II or &gt; congestive heart failure

          -  History of myocardial infarction/unstable angina &lt; 6 months prior to study enrollment

          -  History of stroke/transient ischemic attack &lt; 6 months prior to study enrollment

          -  Significant vascular disease

          -  Symptomatic peripheral vascular disease

          -  Evidence of bleeding diathesis/coagulopathy

          -  Major surgical procedure, open biopsy,/significant traumatic injury within 28 days
             prior to study enrollment/anticipation of need for major surgical procedure during
             course of study

          -  Core biopsy/other minor surgical procedure, excluding placement of vascular access
             device, &lt;7 days prior to study enrollment

          -  History of abdominal fistula, GI perforation, /intra-abdominal abscess &lt;6 months prior
             to study enrollment

          -  Serious, non-healing wound, ulcer, or bone fracture

          -  Proteinuria at screening as demonstrated by either

          -  UPC ratio ≥1.0 at screening OR

          -  Urine dipstick for proteinuria ≥2+

          -  Known hypersensitivity to any component of Avastin

          -  Pregnant/lactating. Use of effective means of contraception in subjects of
             child-bearing potential

          -  Current, ongoing treatment with full-dose warfarin or its equivalent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine B Peters, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cancer.duke.edu/btc/</url>
    <description>The Preston Robert Tisch Brain Tumor Center at DUKE</description>
  </link>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2008</study_first_submitted>
  <study_first_submitted_qc>February 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2008</study_first_posted>
  <results_first_submitted>August 9, 2012</results_first_submitted>
  <results_first_submitted_qc>August 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 10, 2012</results_first_posted>
  <last_update_submitted>May 20, 2013</last_update_submitted>
  <last_update_submitted_qc>May 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioma</keyword>
  <keyword>Temozolomide</keyword>
  <keyword>Temodar</keyword>
  <keyword>Avastin</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>GBM</keyword>
  <keyword>Gliosarcoma</keyword>
  <keyword>Multifocal GBM</keyword>
  <keyword>Brain tumor</keyword>
  <keyword>Unresectable GBM</keyword>
  <keyword>Glioblastoma multiforme</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were accrued between October 2007 and September 2008 within the clinic at Duke Comprehensive Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Avastin and Temozolomide</title>
          <description>Avastin administered at 10 mg/kg every 2 weeks beginning a minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide dosed at 200 mg/m2 daily for 5 days in a 28-day cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Avastin and Temozolomide</title>
          <description>Avastin administered at 10 mg/kg every 2 weeks beginning a minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide dosed at 200 mg/m2 daily for 5 days in a 28-day cycle.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>The proportion of subjects with complete or partial response as determined by a modification of the RANO (Response Assessment in Neuro-Oncology) criteria. A confirmation of response was not required. Complete Response was defined as complete disappearance on MR/CT of all enhancing tumor and mass effect, off all corticosteroids (or receiving only adrenal replacement doses), accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks. Partial Response was defined as greater than or equal to 50% reduction in tumor size on MR/CT by bi-dimensional measurement, on a stable or decreasing dose of corticosteroids, accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks.</description>
        <time_frame>4 months</time_frame>
        <population>All subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Avastin and Temozolomide</title>
            <description>Avastin administered at 10 mg/kg every 2 weeks beginning a minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide dosed at 200 mg/m2 daily for 5 days in a 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>The proportion of subjects with complete or partial response as determined by a modification of the RANO (Response Assessment in Neuro-Oncology) criteria. A confirmation of response was not required. Complete Response was defined as complete disappearance on MR/CT of all enhancing tumor and mass effect, off all corticosteroids (or receiving only adrenal replacement doses), accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks. Partial Response was defined as greater than or equal to 50% reduction in tumor size on MR/CT by bi-dimensional measurement, on a stable or decreasing dose of corticosteroids, accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks.</description>
          <population>All subjects</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" lower_limit="12.4" upper_limit="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>CTCAE (3.0) was used for collecting adverse events in this study. However, the events have been converted to CTCAE (4.0) for entry into clinicaltrials.gov. Only grade 3, grade 4, and grade 5 adverse events were collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Avastin and Temozolomide</title>
          <description>Avastin administered at 10 mg/kg every 2 weeks beginning a minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide dosed at 200 mg/m2 daily for 5 days in a 28-day cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death: Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Katherine Peters, MD, PhD</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>9196846173</phone>
      <email>katherine.peters@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

